专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

21. 发明申请

WO1997030174A1 COMBINATIONS OF PKC INHIBITORS AND THERAPEUTIC AGENTS FOR TREATING CANCERS 审中-公开
标题翻译： PKC抑制剂和治疗癌症治疗药物的组合
公开(公告)号：WO1997030174A1
公开(公告)日：1997-08-21
申请号：PCT/US1997003341
申请日：1997-02-20
申请人： SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH , SCHWARTZ, Gary, K. , ALBINO, Anthony, P.
发明人： SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH
IPC分类号： C12Q01/18
CPC分类号： G01N33/5011 , A61K49/0004
摘要： This invention provides methods for screening a modulating agent which when combined with antitumor therapeutic agent increases apoptosis in tumor cells. This invention also provides methods for screening antitumor therapeutic agents suitable for combination therapy with protein kinase C inhibitors capable of potentiating apoptosis in tumor cells. This invention further provides different combination therapies comprising the specific protein kinase C inhibitors and the antitumor therapeutic agents.
摘要翻译：本发明提供筛选调节剂的方法，其与抗肿瘤治疗剂组合时增加肿瘤细胞的凋亡。本发明还提供了用于筛选适于与能够增强肿瘤细胞凋亡的蛋白激酶C抑制剂组合治疗的抗肿瘤治疗剂的方法。本发明还提供了包含特异性蛋白激酶C抑制剂和抗肿瘤治疗剂的不同组合疗法。

22. 发明申请

WO1997023645A1 METHODS AND REAGENTS FOR TYPING HLA CLASS I GENES 审中-公开
标题翻译：类型Ⅰ类基因的方法和试剂
公开(公告)号：WO1997023645A1
公开(公告)日：1997-07-03
申请号：PCT/US1996000362
申请日：1996-01-04
申请人： SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH
发明人： SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH , YANG, Soo, Young , CEREB, Nezih
IPC分类号： C12Q01/68
CPC分类号： C12Q1/6881 , C12Q2600/156
摘要： Consensus sequences of introns (1, 2 and 3) from the majority of HLA-A, -B and -C allotypes are identified and used to develop primers located within introns (1 and 3) of these genes. The primers are suitable for locus-specific amplification of the entirety of exons (2 and 3). These primers are also suitable for use as sequencing primers to determine the HLA alleles in sequence-based HLA typing. The primers can be used for amplification of portions of introns 1 or 3 and evaluating the amplified products to determine the allelic type of the HLA-A, HLA-B or HLA-C genes. Preferably, one of the primers has a sequence which provides locus-specific amplification.
摘要翻译：鉴定出来自大多数HLA-A，-B和-C同种异型的内含子（1,2和3）的共有序列，并用于开发位于这些基因的内含子（1和3）内的引物。引物适用于整个外显子（2和3）的位点特异性扩增。这些引物也适用于测序引物，以确定基于序列的HLA分型中的HLA等位基因。引物可用于扩增内含子1或3的部分，并评估扩增产物以确定HLA-A，HLA-B或HLA-C基因的等位基因型。优选地，其中一个引物具有提供基因座特异性扩增的序列。

23. 发明申请

WO1997005283A1 Id AS A DIAGNOSTIC MARKER IN TUMOR CELLS 审中-公开
标题翻译：作为肿瘤细胞中的诊断标记
公开(公告)号：WO1997005283A1
公开(公告)日：1997-02-13
申请号：PCT/US1996012014
申请日：1996-07-19
申请人： SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH
发明人： SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH , BENEZRA, Robert
IPC分类号： C12Q01/68
CPC分类号： G01N33/57496 , C12Q1/6886 , C12Q2600/106
摘要： This invention provides methods for identifying tumors which may be susceptible to treatment by chemotherapy or radiation by detecting the presence of nucleic acid encoding Id in the tumor or by detecting the presence of an Id protein in the tumor and a method for in situ identification of tumors which may be susceptible to treatment by chemotherapy or radiation. This invention also provides antisense oligonucleotides, a pharmaceutical composition comprising an amount of the oligonucleotide, methods of inducing terminal differentiation in a tumor cell, and methods of treating a tumor in a subject.
摘要翻译：本发明提供了通过检测肿瘤中编码Id的核酸的存在或通过检测肿瘤中Id蛋白的存在以及用于原位鉴定肿瘤的方法来鉴定可能易于化疗或放射治疗的肿瘤的方法这可能易受化学疗法或辐射治疗的影响。本发明还提供反义寡核苷酸，包含一定量的寡核苷酸的药物组合物，诱导肿瘤细胞中末端分化的方法，以及治疗受试者肿瘤的方法。

24. 发明申请

WO1996035438A1 ONCOGENE FUSION PROTEIN PEPTIDE VACCINES 审中-公开
标题翻译： ONCOGENE融合蛋白肽疫苗
公开(公告)号：WO1996035438A1
公开(公告)日：1996-11-14
申请号：PCT/US1996006504
申请日：1996-05-08
申请人： SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH , CYTEL CORPORATION , SCHEINBERG, David, A. , SETTE, Alessandro , BOCCHIA, Monica
发明人： SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH , CYTEL CORPORATION
IPC分类号： A61K35/14
CPC分类号： C07K14/47 , A61K39/00 , C07K14/70539 , C07K14/70567 , C07K14/82 , C07K2319/40 , C07K2319/81 , C12N15/62 , G01N33/56977 , G01N33/57426 , G01N33/6878
摘要： Fusion-point spanning peptides, for example BCR-ABL fusion breakpoint peptides associate with chronic myelogenous leukemia (CML), bind major histocompatibility complex molecules, such as HLA class I molecules, and induce cytotoxic T cell proliferation. The breakpoint peptides can be used as vaccines.
摘要翻译：融合点跨越肽，例如与慢性骨髓性白血病（CML）相关的BCR-ABL融合断点肽，结合主要组织相容性复合物分子，如HLA I类分子，并诱导细胞毒性T细胞增殖。断点肽可用作疫苗。

25. 发明申请

WO1996031534A1 ISOLATED NUCLEIC ACID MOLECULES ENCODING p57KIP2 AND USES OF SAME 审中-公开
标题翻译：编码p57
公开(公告)号：WO1996031534A1
公开(公告)日：1996-10-10
申请号：PCT/US1996004563
申请日：1996-04-03
申请人： SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH
发明人： SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH , MASSAGUE, Joan , LEE, Mong-Hong
IPC分类号： C07K14/00
CPC分类号： C07K14/4738 , A61K38/00 , C12N2799/021
摘要： This invention provides an isolated nucleic acid molecule encoding a mammalian p57 . This invention also provides vectors comprising the isolated nucleic acid molecule encoding a mammalian p57 . This invention further provides a host vector system for the production of a mammalian p57 . This invention also provides probes for the isolated nucleic acid molecule encoding a mammalian p57 . This invention provides antibodies directed against a mammalian p57 . This invention also provides transgenic animals comprising isolated nucleic acid molecules encoding a mammalian p57 . Finally, this invention provides different uses of the mammalian p57 .
摘要翻译：本发明提供了编码哺乳动物p57 的分离的核酸分子。本发明还提供了包含编码哺乳动物p57 的分离的核酸分子的载体。本发明还提供了用于产生哺乳动物p57 的宿主载体系统。本发明还提供了编码哺乳动物p57 的分离的核酸分子的探针。本发明提供针对哺乳动物p57 的抗体。本发明还提供包含编码哺乳动物p57 的分离的核酸分子的转基因动物。最后，本发明提供哺乳动物p57 的不同用途。

26. 发明申请

WO1996025436A1 RECOMBINANT HUMAN ANTI-LEWIS B ANTIBODIES 审中-公开
标题翻译：重组人抗反义B抗体
公开(公告)号：WO1996025436A1
公开(公告)日：1996-08-22
申请号：PCT/US1996001611
申请日：1996-02-07
申请人： SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH , SCOTGEN BIOPHARMACEUTICALS INC.
发明人： SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH , SCOTGEN BIOPHARMACEUTICALS INC. , WELT, Sydney , OLD, Lloyd , KITAMURA, Kunio , WALLACE, T., Paul , HARRIS, William, J. , CARR, Frank, J.
IPC分类号： C07K16/30
CPC分类号： C07K16/30 , A61K2039/505 , C07K2317/24 , C07K2319/00
摘要： The invention provides for the production of several humanized murine antibodies specific for the Lewis b antigen, which is recognized by the murine antibody 58-1066. The antigen is expressed on cell lines from colon, lung, bladder, breast, renal, pancreatic and ovarian cancers. The expression of the antigen is greatly increased in cancer tissues as compared to its expression in the corresponding normal tissue. The invention also provides for numerous polynucleotides encoding humanized Lewis b antigen specific antibodies, expression vectors for producing humanized Lewis b antigen specific antibodies, and host cells for the recombinant production of the humanized antibodies. The invention also provides methods for detecting cancerous cells (in vitro and in vivo)using humanized Lewis b antigen specific antibodies. Additionally, the invention provides methods of treating cancer using Lewis b antigen specific antibodies.
摘要翻译：本发明提供了生产针对Lewis b抗原特异性的几种人源化鼠抗体，其被鼠抗体58-1066识别。抗原在结肠癌，肺癌，膀胱癌，乳腺癌，肾癌，胰腺癌和卵巢癌的细胞系中表达。与其相应的正常组织中的表达相比，癌组织中抗原的表达大大增加。本发明还提供编码人源化Lewis B抗原特异性抗体的许多多核苷酸，用于产生人源化Lewis B抗原特异性抗体的表达载体和用于重组产生人源化抗体的宿主细胞。本发明还提供使用人源化Lewis B抗原特异性抗体检测癌细胞（体外和体内）的方法。另外，本发明提供了使用Lewis b抗原特异性抗体治疗癌症的方法。

27. 发明申请

WO1996019497A1 METHOD FOR MOLECULAR CLONING AND POLYNUCLEOTIDE SYNTHESIS USING VACCINIA DNA TOPOISOMERASE 审中-公开
标题翻译：使用VACCINIA DNA TOPOISOMERASE进行分子克隆和多核苷酸合成的方法
公开(公告)号：WO1996019497A1
公开(公告)日：1996-06-27
申请号：PCT/US1995016099
申请日：1995-12-12
申请人： SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH
发明人： SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH , SHUMAN, Stewart
IPC分类号： C07K14/07
CPC分类号： C07K14/005 , A61K38/00 , C07K2319/21 , C12N9/90 , C12N15/10 , C12N15/64 , C12N15/66 , C12N2710/24122
摘要： This invention provides a modified vaccinia topoisomerase enzyme containing an affinity tag which is capable of facilitating purification of protein-DNA complexes away from unbound DNA. This invention further provides a modified sequence specific topoisomerase enzyme. This invention provides a method of ligating duplex DNAs, a method of molecular cloning of DNA, a method of synthesizing polynucleotides, and a method of gene targeting. Lastly, this invention provides a recombinant DNA molecule composed of segments of DNA which have been joined ex vivo by the use of a sequence specific topoisomerase and which has the capacity to transform a suitable host cell comprising a DNA sequence encoding polypeptide activity.
摘要翻译：本发明提供了含有亲和标签的修饰的痘苗拓扑异构酶，其能够促进蛋白质-DNA复合物远离未结合的DNA的纯化。本发明进一步提供了修饰的序列特异性拓扑异构酶。本发明提供了连接双链DNA的方法，DNA的分子克隆方法，合成多核苷酸的方法以及基因靶向方法。最后，本发明提供了由DNA片段组成的重组DNA分子，其已经通过使用序列特异性拓扑异构酶离体结合并且具有转化包含编码多肽活性的DNA序列的合适宿主细胞的能力。

28. 发明申请

WO1996016655A1 NOVEL ENEDIYNE QUINONE IMINES AND METHODS OF PREPARATION AND USE THEREOF 审中-公开
标题翻译：新型ENEDIYNE QUINONE IMINES及其制备和使用方法
公开(公告)号：WO1996016655A1
公开(公告)日：1996-06-06
申请号：PCT/US1995015678
申请日：1995-12-01
申请人： SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH , DANISHEFSKY, Samuel, J. , SHAIR, Matthew, D. , YOON, Taeyoung , CHOU, Ting-Chao , MOSNY, Karoline, K.
发明人： SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH
IPC分类号： A61K31/47
CPC分类号： C07D491/08 , A61K47/6803 , A61K47/6809
摘要： A quinone imine enediyne possessing cytotoxic activity towards cancer cells having general structure (I) wherein R1, R2 and R3 are independently the same or different and are H, Br, Cl, F, NH2, CO2H, OH, linear or branched alkyl, etc.; wherein R4 is H, OH or linear or branched alkoxy, linear or branched alkoxycarbonyl, etc.; wherein R5 is H, Br, Cl, F, O=, OH or S-SR, or linear or branched alkyl, etc.; wherein R6 is H, Br, Cl, F, CO2H, OH or S-SR', or linear or branched alkyl, etc.; wherein R7 is H, OH or S-SR", or linear or branched alkyl, linear or branched alkoxycarbonyl, linear or branched alkoxy or linear or branched hydroxyalkyl; and wherein R, R' and R" are independently the same or different and are linear or branched alkyl, linear or branched acyl or linear or branched alkoxyalkyl. Also provided are conjugates of the compound with cleavable peptides, enzymes, carbohydrates and monoclonal antibodies immunoreactive with cancer cells, as well as compositions comprising the analogues and conjugates, and methods of synthesis and treatment of tumors.
摘要翻译：对具有通式（I）的具有通式结构（I）的癌细胞具有细胞毒性活性的醌亚胺enediyne，其中R 1，R 2和R 3独立地相同或不同，为H，Br，Cl，F，NH 2，CO 2 H，OH，直链或支链烷基等。其中R4是H，OH或直链或支链烷氧基，直链或支链烷氧基羰基等; 其中R 5为H，Br，Cl，F，O =，OH或S-SR，或直链或支链烷基等; 其中R6是H，Br，Cl，F，CO2H，OH或S-SR'，或直链或支链烷基等; 其中R 7是H，OH或S-SR“，或直链或支链烷基，直链或支链烷氧基羰基，直链或支链烷氧基或直链或支链羟烷基;其中R，R'和R”独立地相同或不同，直链或支链烷基，直链或支链酰基或直链或支链烷氧基烷基。还提供了化合物与可切割肽，酶，碳水化合物和与癌细胞免疫反应的单克隆抗体的缀合物，以及包含类似物和缀合物的组合物，以及合成和治疗肿瘤的方法。

29. 发明申请

WO1996000779A1 PROCESS FOR EX VIVO EXPANSION OF HEMATOPOIETIC PROGENITOR CELLS 审中-公开
标题翻译：血细胞生成素细胞扩增的方法
公开(公告)号：WO1996000779A1
公开(公告)日：1996-01-11
申请号：PCT/US1995008031
申请日：1995-06-26
申请人： CORNELL RESEARCH FOUNDATION, INC. , SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH
发明人： CORNELL RESEARCH FOUNDATION, INC. , SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH , ASCH, Adam, S. , MOORE, Malcom, A., S. , RAFII, Shahin , SHAPIRO, Fred
IPC分类号： C12N05/00
CPC分类号： C12N5/0647 , C12N5/0644 , C12N2501/01 , C12N2501/02 , C12N2502/28
摘要： The present inention relates to a process for ex vivo expansion of hematopoietic progenitor cells. This process is particularly useful in conjunction with a process for conducting autologous hematopoietic progenitor cell transplantation. In this process, hematopoietic progenitor cells are obtained from a patient prior to cytoreductive therapy. The hematopoietic progenitor cells are then expanded ex vivo with bone marrow endothelial cells or with one or more cytokines therefrom to produce a cellular preparation with an increased number of hematopoietic progenitor cells. The cellular preparation is then administered to the patient in conjunction with or after cytoreductive therapy.
摘要翻译：本发明涉及造血祖细胞离体扩增的方法。该方法特别适用于进行自体造血祖细胞移植的方法。在该过程中，在细胞减灭治疗之前从患者获得造血祖细胞。然后使用骨髓内皮细胞离体扩增造血祖细胞，或用一种或多种细胞因子扩增造血祖细胞以产生具有增加造血祖细胞数量的细胞制剂。然后将细胞制剂与细胞减少疗法联合或之后施用于患者。

30. 发明申请

WO1995034307A1 CERAMIDE-ACTIVATED PROTEIN KINASE AND METHODS OF USE OF EFFECTORS 审中-公开
标题翻译：陶瓷活化蛋白激酶和使用效应的方法
公开(公告)号：WO1995034307A1
公开(公告)日：1995-12-21
申请号：PCT/US1995007405
申请日：1995-06-07
申请人： SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH , KOLESNICK, Richard, N. , GOLDE, David, W.
发明人： SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH
IPC分类号： A61K33/00
CPC分类号： C12N9/1205 , A61K38/191 , A61K38/2006 , C12Q1/48
摘要： A purified membrane-bound ceramide-activated protein kinase having a mass of 97 kDa as determined by SDS PAGE has been obtained. This kinase specifically phosphorylates threonine in the sequence, Pro-Leu-Thr-Pro-containing polypeptides. A method for determining if an effector specifically inhibits or stimulates the phosphorylating activity of the kinase is presented. Methods are provided for using said effector that inhibit or stimulate the kinase to treat a subject having inflammatory disorder, to reduce the proliferation of HIV in human subject, or to treat poor stem cell growth. A method for determining if an agent can inhibit the lipopolysaccharide stimulation of the kinase is also presented. Additionally a method of treating a subject suffering from lipopolysaccharide-related disorder with said agent is presented.
摘要翻译：已经获得了通过SDS PAGE测定的质量为97kDa的纯化的膜结合的神经酰胺活化蛋白激酶。该激酶特异性地使序列中的苏氨酸磷酸化，即含有Pro-Leu-Thr-Pro的多肽。提出了确定效应物是否特异性抑制或刺激激酶的磷酸化活性的方法。提供了使用抑制或刺激激酶治疗患有炎性病症的受试者，减少人受试者中HIV的增殖或治疗差的干细胞生长的方法。还提出了用于确定试剂是否能抑制激酶的脂多糖刺激的方法。另外，提出了用所述药物治疗患有脂多糖相关病症的受试者的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式